Department of Studies in Biotechnology, University of Mysore, Manasagangotri, Mysore-570 006, India.
Department of Biotechnology, Teresian College, Siddarthanagar, Mysore-570011, India.
Anticancer Agents Med Chem. 2018 Feb 7;17(14):1931-1941. doi: 10.2174/1871521409666170412120837.
Quinazolines are a big family of heterocyclic compounds with anti-cancer properties.
The latest investigation was on synthesis, characterization of novel 4-anilinoquinazoline derivatives for their anti-angiogenic effect.
A series of novel 4-anilino-6,7-dimethoxy quinazoline derivatives were synthesized and characterized using 1H, 13C NMR, FT-IR and LC-MS techniques. Cytotoxicity assays were performed for all compounds against different cell lines such as Human colon carcinoma (HCT116), Human chronic myeloid leukemia (K562) and Human breast cancer (SKBR3) cell lines using 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl tetrazolium Bromide (MTT), Trypan blue and Lactose dehydrogenase release assay. The selected compounds were evaluated for their anti-tumor and anti-angiogenic effect on EAC tumor model. The molecular docking studies were drawn using maestro 2D sketcher and energy minimize was compounded by OPLS 2005.
Among all compounds, RB4 and RB7 showed moderate activity whereas RB1 showed most potent activity comparable with that of the standard drug cisplatin against all three cell lines. RB1 also inhibited the proliferation of tumor cells in three different cell lines. Further, in-vivo studies revealed that RB1 significantly reduced secretion of ascites, tumor cell proliferation and increased the life span of tumor bearing mice. The antiangiogenic effect of RB1 was revealed from the reduced vessel sprouting in the peritoneum region of treated mice and induced avascular zone in chorioallantoic membrane (CAM) model. The insilco molecular docking studies clearly demonstrate the dual inhibitory potential of RB1 against VEGFR-2 and EGFR from binding to the active site of its receptors.
However these studies clearly show that RB1 might be a potent antitumor and anti-angiogenic agent representing a promising lead for further optimization and elucidation of the mechanism of action.
喹唑啉是具有抗癌特性的杂环化合物大家族。
最新的研究是合成、表征新型 4-苯胺基喹唑啉衍生物,研究其抗血管生成作用。
采用 1H、13C NMR、FT-IR 和 LC-MS 技术合成并表征了一系列新型 4-苯胺基-6,7-二甲氧基喹唑啉衍生物。采用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)、台盼蓝和乳酸脱氢酶释放测定法,对所有化合物进行了对不同细胞系(人结肠癌细胞(HCT116)、人慢性髓系白血病(K562)和人乳腺癌(SKBR3)细胞系)的细胞毒性测定。对选定的化合物进行了 EAC 肿瘤模型的抗肿瘤和抗血管生成作用评价。使用 maestro 2D sketcher 进行分子对接研究,并使用 OPLS 2005 进行能量最小化复合。
在所研究的所有化合物中,RB4 和 RB7 表现出中等活性,而 RB1 表现出最有效的活性,与标准药物顺铂相当,对三种细胞系均有活性。RB1 还抑制了三种不同细胞系中肿瘤细胞的增殖。此外,体内研究表明,RB1 可显著减少腹水分泌、肿瘤细胞增殖,并延长荷瘤小鼠的寿命。RB1 的抗血管生成作用是通过减少处理小鼠腹膜区域的血管芽生和诱导绒毛尿囊膜(CAM)模型中的无血管区来揭示的。分子对接研究表明,RB1 对 VEGFR-2 和 EGFR 的双重抑制作用可能源于其与受体活性部位的结合。
然而,这些研究清楚地表明,RB1 可能是一种有效的抗肿瘤和抗血管生成药物,为进一步优化和阐明作用机制提供了有前途的先导化合物。